(A) Effect of THC on p70S6K and S6 phosphorylation of U87MG cells
(n = 6). (B) Effect of THC on cell viability
(left panel; 24 h; mean ± SD; n = 6) and LC3
lipidation (right panel; 18 h; n = 4) in
Tsc2+/+ and
Tsc2–/– MEFs.
(C) Effect of THC on Akt, TSC2, PRAS40, p70S6K, and S6
phosphorylation of U87MG cells (18 h; OD relative to vehicle-treated cells, mean
± SD; n = 7). (D) Effect of THC on cell
viability (left panel; 24 h; mean ± SD; n = 4) and
LC3 lipidation (right panel; 18 h; n = 4) of pBABE and
myristoylated Akt (myr-Akt) MEFs. (E) Effect of THC on Akt
co-immunoprecipitation with TRB3 in U87MG cell extracts (8 h; OD relative to
vehicle-treated cells, mean ± SD; n = 9; input:
TRB3). (F and G) Effect of THC on Akt, TSC2, PRAS40,
p70S6K, and S6 phosphorylation and LC3 lipidation (G only) of siC-
and siTRB3-transfected (F; 18 h; OD relative to vehicle-treated
siC-transfected U87MG cells, mean ± SD; n = 7; upper
panel shows an analysis of TRB3 mRNA levels) and EGFP (Ad-EGFP) or rat TRB3
(Ad-TRB3) adenoviral vector–infected (G; 18 h; OD
relative to vehicle-treated Ad-EGFP–infected U87MG cells, mean
± SD; n = 4; upper panel shows an analysis of rTRB3
mRNA levels) U87MG cells. (H) Effect of THC on Akt, p70S6K, and S6
phosphorylation of p8+/+ and
p8–/– MEFs
(n = 7). *P < 0.05 and **P
< 0.01 compared with THC-treated
Tsc2+/+ (B) and pBABE (D)
MEFs and compared with vehicle-treated (C and E),
vehicle-treated siC-transfected (F), or Ad-EGFP–infected
(G) U87MG cells.